Study to predict cancer return risk in stage III kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study is testing a new scoring system to see if it can help predict the risk of cancer coming back in people with stage III clear cell kidney cancer. If you qualify, the study team will use your medical information to see if this scoring system could help guide future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III clear cell kidney cancer (the most common type of kidney cancer).
- Your cancer was completely removed with surgery, and no cancer cells were left behind at the edges of the removed tissue.
- You are healthy enough for daily activity (ECOG score 0 or 1).
- You have not received any cancer treatment before your kidney surgery.
- You are not pregnant or breastfeeding, and you do not have serious health problems like heart disease, severe diabetes, or kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking axitinib plus an immunotherapy drug (PD-1) before surgery can help people with kidney cancer live longer without the cancer coming back. It’s focused on people who have a higher-risk kidney tumor based on scans and pathology findings.
This study looks at patients with kidney cancer that hasn't spread and is considered high-risk. It uses a registry to learn more about these patients to improve future care.
This trial tests a first-line precision treatment for clear cell kidney cancer that has spread or cannot be removed. It aims to match the treatment to your cancer's protein profile to improve outcomes.
This trial checks whether a CpG-methylation test can help sort people with stage III clear cell kidney cancer who are planning adjuvant (after-surgery) treatment. It may help doctors choose the most appropriate follow-up plan based on your cancer’s risk pattern.
This study is checking how well a model can predict the outcomes for people with kidney cancer who have had surgery. It looks at your medical records after surgery to help doctors better understand your recovery and future risks.
This trial tests whether extra treatment after surgery can help people with a certain type of kidney cancer (stage III papillary kidney cancer) that is at high risk of coming back. The goal is to see if this approach improves outcomes.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.